Evaluation of the Adjuvant Activity of Propranolol, a Beta-Adrenergic Receptor Antagonist, on Efficacy of a Malaria Vaccine Model in BALB/c Mice
-
Shahram Shahabi
,
Habib Mohammadzadeh Hajipirloo
,
Seyed Ahmad Keramati
,
Khosrow Hazrati Tappeh
,
Arezoo Bozorgomid
Abstract
We have previously shown the adjuvant activity of propranolol (PRP) (a beta-adrenergic receptor antagonist) using a vaccine model for Salmonella typhimurium. In this study PRP was used as an adjuvant in combination with Plasmodium berghei (P. berghei) whole blood stage (PWBS) antigens.
BALB/c mice were immunized three times with a 2-week interval, either PWBS vaccine alone or in combination with the adjuvant alum or propranolol. The control group received phosphate buffered saline. Evaluation of the cellular and humoral immunity was performed by measurement of interferon (IFN)-γ, tumor necrosis factor (TNF)-α, lymphocyte proliferation, total IgG and IgG2a in the control and immunized groups. Furthermore, Clinical evaluations were carried out by analyze survival rate and parasitemia of the mice.
Our results showed that the mice immunized with propranolol induced higher levels of antibody, IFN-γ and TNF-α as well as stronger lymphocyte proliferative responses compared with other groups. This resulted in improved protective immunity against Plasmodium berghei.
Administration of the PRP as an adjuvant in combination with the PWBS Antigen vaccine can shift the immune responses to a T helper1 pattern and enhance the protective immunity.
1. WHO. World Malaria Report 2012,. http://www.who.int/malaria/world-malaria-report-2012/en/.
2. Klein EY. Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents 2013; 41(4):311-7.
3. Santos G, Torres NV. New targets for drug discovery against malaria. PLoS One 2013; 8(3):e59968.
4. Crompton PD, Pierce SK, Miller LH. Advances and challenges in malaria vaccine development. J Clin Invest 2010; 120(12):4168-78.
5. De Gregorio E, Tritto E, Rappuoli R. Alum adjuvanticity:unraveling a century old mystery. Eur J Immunol 2008;38(8):2068-71.
6. Tagliabue A, Rappuoli R. Vaccine adjuvants: the dream becomes real. Hum Vaccin 2008; 4(5):347-9.
7. Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int J Pharm 2008;364(2):272-80.
8. Harandi AM, Medaglini D, Shattock RJ. Vaccine adjuvants: a priority for vaccine research. Vaccine 2010;28(12):2363-6.
9. Lindblad EB. Aluminium compounds for use in vaccines.Immunol Cell Biol 2004; 82(5):497-505.
10. Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30(1):23-32.
11. Jacobs P, Radzioch D, Stevenson MM. A Th1-associated increase in tumor necrosis factor alpha expression in the spleen correlates with resistance to blood-stage malaria in mice. Infect Immun 1996; 64(2):535-41.
12. Matsumoto S, Yukitake H, Kanbara H, Yamada H, Kitamura A, Yamada T. Mycobacterium bovis bacillus calmette-guerin induces protective immunity against infection by Plasmodium yoelii at blood-stage depending on shifting immunity toward Th1 type and inducingprotective IgG2a after the parasite infection. Vaccine 2000; 19(7-8):779-87.
13. Stevenson MM, Tam MF. Differential induction of helper T cell subsets during blood-stage Plasmodium chabaudi AS infection in resistant and susceptible mice. Clin Exp Immunol 1993; 92(1):77-83.
14. Su Z, Tam MF, Jankovic D, Stevenson MM. Vaccination with novel immunostimulatory adjuvants against blood- stage malaria in mice. Infect Immun 2003; 71(9):5178-87.
15. Torre D, Speranza F, Giola M, Matteelli A, Tambini R, Biondi G. Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clinical and diagnostic laboratory immunology2002; 9(2):348-51.
16. Tyagi RK, Garg NK, Sahu T. Vaccination Strategies against Malaria: novel carrier(s) more than a tour de force. J Control Release 2012; 162(1):242-54.
17. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997; 100(6):1513-9.
18. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998; 4(7):808-13.
19. Steinman L. Elaborate interactions between the immune and nervous systems. Nat Immunol 2004; 5(6):575-81.
20. Engler KL, Rudd ML, Ryan JJ, Stewart JK, Fischer- Stenger K. Autocrine actions of macrophage-derived catecholamines on interleukin-1 beta. J Neuroimmunol.2005;160(1-2):87-91.
21. Sitkauskiene B, Sakalauskas R. The role of beta(2)- adrenergic receptors in inflammation and allergy. Curr Drug Targets Inflamm Allergy 2005; 4(2):157-62.
22. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000; 52(4):595-638.
23. Bellinger DL, Millar BA, Perez S, Carter J, Wood C, ThyagaRajan S, et al. Sympathetic modulation of immunity: relevance to disease. Cell Immunol 2008;252(1-2):27-56.
24. Mazloomi E, Jazani NH, Shahabi S. A novel adjuvant, mixture of alum and the beta-adrenergic receptor antagonist propranolol, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. Vaccine 2012; 30(16):2640-6.
25. Mota MM, Thathy V, Nussenzweig RS, Nussenzweig V.Gene targeting in the rodent malaria parasite Plasmodium yoelii. Mol Biochem Parasitol 2001; 113(2):271-8.
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2):55-63.
27. Nussenblatt V, Mukasa G, Metzger A, Ndeezi G, Garrett E, Semba RD. Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated Plasmodium falciparum malaria. Clin Diagn Lab Immunol 2001; 8(6):1164-70.
28. Grebe KM, Hickman HD, Irvine KR, Takeda K, Bennink JR, Yewdell JW. Sympathetic nervous system control of anti-influenza CD8+ T cell responses. Proc Natl Acad Sci U S A 2009; 106(13):5300-5.
29. Khalili A, Hassan ZM, Shahabi S, Pourfathollah AA, Ostad SN, Noori S, et al. Long Acting Propranolol and HSP-70 Rich Tumor Lysate Reduce Tumor Growth and Enhance Immune Response against Fibrosarcoma in Balb/c Mice. Iran J Immunol 2013; 10(2):70-82.
30. Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother 1965; 25(3):577-91.
31. Ware WA,. Cardiovascular disease in small animal medicine. London: Manson Publishing Ltd; 2007.
32. Peek EJ, Richards DF, Faith A, Lavender P, Lee TH, Corrigan CJ, et al. Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. Am J Respir Cell Mol Biol 2005; 33(1):105-11.
33. Vida G, Pena G, Kanashiro A, Del Rocio Thompson- Bonilla M, Palange D, Deitch EA, et al. {beta}2- Adrenoreceptors of regulatory lymphocytes are essential for vagal neuromodulation of the innate immune system. FASEB J 2011; 25(12):4476-85
34. Malec P, Markiewicz K, Tchorzewski H, Zeman K, Baj Z, Nowak Z, et al. The stimulatory effect of a single intravenous dose of propranolol of some immune parameters in humans. Allergol Immunopathol (Madr)1988; 16(2):85-9.
35. Houot R, Perrot I, Garcia E, Durand I, Lebecque S.Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 2006; 176(9):5293-8.
36. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006;7(1):83-92.
37. Bayry J, Triebel F, Kaveri SV, Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction withCD4+CD25+ regulatory T cells. J Immunol 2007;178(7):4184-93.
38. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri SV, et al. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. Proc Natl Acad Sci U S A 2008;105(29):10221-6.
39. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, et al. Toward the discovery of vaccine adjuvants: coupling in silico screening and in vitro analysis of antagonist binding to human and mouse CCR4 receptors. PLoS One 2009; 4(11):e8084.
40. Jamali A, Mahdavi M, Hassan ZM, Sabahi F, Farsani MJ, Bamdad T, et al. A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int Immunol 2009;21(3):217-25.
41. Jazani NH, Karimzad M, Mazloomi E, Sohrabpour M, Hassan ZM, Ghasemnejad H, et al. Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect 2010; 12(5):382-8.
42. Jazani NH, Parsania S, Sohrabpour M, Mazloomi E, Karimzad M, Shahabi S. Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella yphimurium infection. Immunobiology 2011; 216(6):744-51.
43. Jazani NH, Sohrabpour M, Mazloomi E, Shahabi S. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol.2010;61(1):54-62.
44. Molla Hassan AT, Hassan ZM, Moazzeni SM, Mostafaie A, Shahabi S, Ebtekar M, et al. Naloxone can improve the anti-tumor immunity by reducing the CD4+CD25+Foxp3+ regulatory T cells in BALB/c mice. Int Immunopharmacol 2009; 9(12):1381-6.
45. van Rooijen N. Antigen processing and presentation in vivo: the microenvironment as a crucial factor. Immunol Today 1990; 11(12):436-9.
46. Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2006; 42(1):1-11.
47. http://www.accessdata.fda.gov. Drugs@FDA- FDA Approved Drug Products. 2011 [cited 2011].
| Files | ||
| Issue | Vol 13, No 5 (2014) | |
| Section | Articles | |
| Keywords | ||
| Adjuvant Beta-adrenergic receptor Malaria Plasmodium berghei Propranolol Vaccine | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
